Press Releases
September 19, 2024
Published by Melanie Hurley Iveagh at September 19, 2024
Categories
Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]
April 19, 2024
Published by Melanie Hurley Iveagh at April 19, 2024
Categories
Dublin, Ireland, 19 April 2024: Afimmune announced today its collaborative partnership with Pathway to Cures (P2C) to support the development of Epeleuton as a potential therapeutic […]
November 8, 2023
Published by Melanie Hurley Iveagh at November 8, 2023
Categories
Dublin, Ireland, 8 November 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that recruitment has commenced in the first clinical […]
September 18, 2023
Published by Melanie Hurley Iveagh at September 18, 2023
Categories
Dublin, Ireland, 18 September 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted […]
June 19, 2023
Published by Melanie Hurley Iveagh at June 19, 2023
Categories
Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to join the Sickle Cell Disease […]
June 5, 2023
Published by Melanie Hurley Iveagh at June 5, 2023
Categories
Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology […]
March 29, 2023
Published by Melanie Hurley Iveagh at March 29, 2023
Categories
Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]
January 4, 2023
Published by Melanie Hurley Iveagh at January 4, 2023
Categories
Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]
September 19, 2022
Published by Melanie Hurley Iveagh at September 19, 2022
Categories
Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]
July 19, 2022
Published by Melanie Hurley Iveagh at July 19, 2022
Categories
Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
June 10, 2022
Published by Melanie Hurley Iveagh at June 10, 2022
Categories
Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
May 13, 2022
Published by micadmin at May 13, 2022
Categories
Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]
August 26, 2021
Published by Melanie Hurley Iveagh at August 26, 2021
Categories
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]
December 18, 2018
Published by Adelle McGourty at December 18, 2018
Categories
Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]
October 18, 2017
Published by micadmin at October 18, 2017
Categories
Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]